The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Open accessAbstract
BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS: One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS: With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION: With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationAdjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Self-citationAdjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Self-citationEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Self-citationHudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Self-citationAshworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
Self-citation
Cited by
Yamauchi, H., Toi, M., Takayama, S., Nakamura, S., Takano, T., Cui, K., Campbell, C., De Vos, L., Geyer, C., & Tutt, A. (2023) · Breast Cancer · doi:10.1007/s12282-023-01451-8 · Cited by 13
Self-citationClinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer
Lynce, F., & Robson, M. (2023) · Cancer Treatment and Research · doi:10.1007/978-3-031-30065-3_6 · Cited by 4
Metadata
- Authors
- Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmaña, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S.-A., Jager, A., Jóhannsson, Ó. Þ., Lakhani, S. R., Janni, W., Linderholm, B., Liu, T.-W., Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marmé, F., Martinez de Dueñas, E., McConnell, R., Phillips, K.-A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Španić, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J., Sevelda, P., Haslbauer, F., Penzinger, M., Öhler, L., Tinchon, C., Greil, R., Heibl, S., Bartsch, R., Wette, V., Singer, C. F., Pasterk, C., Helfgott, R., Pristauz-Telsnigg, G., Stöger, H., Weltermann, A., Egle, D., Thiel, I., Fuchs, D., Rumpold, H., Strasser-Weippl, K., Rautenberg, B., Müller, V., Schmidt, M., Paepke, S., Aydogdu, M., Thomssen, C., Rom, J., Mau, C., Fasching, P., Göhring, U.-J., Kühn, T., Noeding, S., Kümmel, S., Hackmann, J., Stickeler, E., Joshi, A., Dewar, J., Friedlander, M., Phillips, K.-A., Antill, Y., Woodward, N., Abdi, E., Tiley, S., George, M., Boadle, D., Goodwin, A., van der Westhuizen, A., Kannourakis, G., Murray, N., McCarthy, N., Kroep, J., de Boer, M., Heijns, J., Jager, A., Erdkamp, F., Bakker, S., Sonke, G. S., Sami, A., Mackey, J., Prady, C., Eisen, A., Desbiens, C., Patocskai, E., Ferrario, C., Gelmon, K., Bordeleau, L., Chalchal, H., Niraula, S., wolf, I., Senkus, E., Duhoux, F., d’Hondt, R., Luce, S., Roodenbeke, D. T. D., Papadimitriou, K., Borms, M., Quaghebeur, C., Jacot, W., Brain, E., Venat-Bouvet, L., Lortholary, A., Nowecki, Z., Cardoso, F., Hayward, R., Bella, S., Lazzaro, M. F., Pilnik, N., Fein, L. E., Blajman, C., Lerzo, G., Varela, M., Zarba, J. J., Kaen, D., Constanzo, M. V., Tio, J., Siggelkow, W., Jackisch, C., Grischke, E. M., Zahm, D., Tato-Varela, S., Schmatloch, S., Klare, P., Stefek, A., Rhiem, K., Hoffmann, O., Kümmel, S., Deryal, M., Gröll, I., Ledwon, P., Uleer, C., Krabisch, P., Potenberg, J., Darsow, M., Park-Simon, T.-W., Höffkes, H.-G., Emde, T.-O., Graffunder, G., Tomé, O., Forstmeyer, D., Terhaag, J., Salat, C., Kast, K., Weniger, S., Schreiber, C., Heinrich, B., Dieterich, M., Wüllner, M. P., Conejero, R. A., García Sáenz, J. Á., Martinez, L. C., Lanza, A. A., Murillo, S. M., Carrasco, F. H., Tormo, S. B., López, I. Á., Delgado Mingorance, J. I., Gomez, E. Á., Santisteban, M., Jurado, J. C., Quiroga, V., Borrego, M. R., Martínez de Dueñas, E., Alés Martínez, J. E., De la Haba, J., Jañez, N. M., Lescure, Á. R., Torres, A. A., Crusades, G. L., González-Santiago, S., Aragones, A. M., Ortega, A. L., Molins, A. B., Chacón López-Muñiz, J. I., Jiménez, M. M., Bertrán, A. S., Rodríguez, C., Cortijo, L. G., Cretella, E., Cortesi, L., Ruggeri, E. M., Verusio, C., Gori, S., Bonetti, A., Mosconi, A. M., Johannsson, O., Jerusalem, G., Neven, P., Nagy, T., Pinotti, G., Colleoni, M. A., Bernardo, A., Gianni, L., Bucci, E., Biganzoli, L., Dedes, K., Novak, U., Zaman, K., Braybrooke, J., Winter, M., Rea, D., Kelleher, M., Barrett, S., Chan, S., Hickish, T., Hurwitz, J., Conibear, J., Jegannathen, A., Parton, M., Tutt, A., Allerton, R., Borley, A., Armstrong, A., Copson, E., Levitt, N., Abraham, J., Perren, T., Roylance, R., Ishida, K., Toyama, T., Masuda, N., Watanabe, J., Tokunaga, E., Kinoshita, T., Rai, Y., Takada, M., Yanagita, Y., Nakamura, R., Nakayama, T., Naoi, Y., Iwata, H., Nakamura, S., Takahashi, M., Aogi, K., Tsugawa, K., Mukai, H., Takano, T., Osaki, A., Sato, N., Yamauchi, H., Tokuda, Y., Ito, M., Sugimoto, T., Bahadur, S. W., Ganz, P. A., Lu, M. J., Lu, M. J., Mita, M. M., Waisman, J., Polikoff, J. A., Telli, M. L., Seaward, S. A., Suga, J. M., Seaward, S. A., Suga, J. M., Durna, L. N., Carney, J. F., Menter, A., Suga, J. M., Puthillath, A., Polikoff, J. A., Suga, J. M., Rohatgi, N., Suga, J. M., Polikoff, J. A., Polikoff, J. A., Feusner, J. H., Bobolis, K. A., Polikoff, J. A., Eisenberg, P. D., Suga, J. M., Polikoff, J. A., Wong, D., Borges, V. F., Urquhart, A. T., Hofstatter, E. W., Hofstatter, E. W., Hofstatter, E. W., McCarron, E. C., Isaacs, C., Herbolsheimer, P., Varadarajan, R., Raben, A., Deveras, R. A. E., Valdes-Albini, F., Mahtani, R. L., Mahtani, R. L., Meisel, J. L., Sumrall, B. T., Jones, C. F., Ofori, S. N., Sumida, K. N. M., Sumida, K. N. M., Karwal, M., Wilbur, D. W., Singh, (., Spector, D. M., Schallenkamp, J., Merkel, D. E., Lo, S. S., Khosla, P. G., Cristofanilli, M., Flaum, L., Hoskins, K. F., Cobleigh, M. A., Lambiase, E. A., Hahn, O. M., Oliff, I. A., Faller, B. A., Wade, J. L., Burhani, N. D., Wade, J. L., Gil, A., Einhorn, H. E., Storniolo, A. M. V., Chang, B. K., Kalra, M., Robin, E. L., Ansari, B., Sharma, P., Dakhil, S. R., Dakhil, S. R., Deming, R. L., Cole, J. T., Cole, J. T., Cole, J. T., Hanson, D. S., Ochoa, A. C., Cole, J. T., Ochoa, A. C., Garber, J. E., Garber, J. E., Zimbler, H., Armstrong, D. K., Tkaczuk, K. H. R., Riseberg, D. A., Armstrong, D. K., O'Connor, B. M., Openshaw, T. H., Openshaw, T. H., Openshaw, T. H., Zakalik, D., Vakhariya, C. M., Schott, A. F., Simon, M. S., Doyle, T. J., Al Baghdadi, T., VanderWoude, A., Flynn, P. J., Zera, R. T., Friday, B. E. B., Ruddy, K. J., Zera, R. T., Smith, R., Flynn, P. J., Ademuyiwa, Olabisi, F., Ellis, R., Carlson, J. W., Carlson, J. W., Marchello, T, B., Levine, E. A., Marcom, P. K., Harkness, C. B., Tan, A. R., Charles, W. J., Kuzma, C. S., Asaad, S., Radford, J. E., Steen, P. D., Unnikrishnan, M., Seeger, G. R., Leu, K. M. H., Copur, M. S., Hauke, R. J., Soori, G. S., Hauke, R. J., Arrick, B. A., Reeder, J. G., Toppmeyer, D. L., Dayao, Z. R., Adams, S., Andreopoulou, E., Allison, M., Anampa Mesias, J. D., Sharma, R., Ramaswamy, B., Gerds, A. T., Shenk, R. R., Gross, H. M., Trehan, S., Gross, H. M., Gross, H. M., Gross, H. M., Shenk, R. R., Gross, H. M., Shenk, R. R., Razaq, W., Mansoor, A. H., Hilton, C. J., Brufsky, A. M., Huynh, C., Chowdhury, N., Domchek, S. M., Sigurdson, E. R., Cescon, T. P., Rovito, M. A., DeNittis, A. S., Vogel, V. G., Julian, T. B., Boyle, L. E., Baez-Diaz, L., Brescia, F. J., Doster, J. E., Siegel, R. D., Wong, L., Patel, T., Nangia, J. R., Jones, C. A., Cannon, G. M., Cannon, G. M., Bear, H. D., Vachhani, H., Wilkinson, M., Wood, M. E., Wood, M. E., Yan, F., Sui, X., van Haelst, C. M., Specht, J. M., Zhuo, Y., Qamar, R., Ryan, M. L., Stockham, A., Virani, S., Qamar, R., Gayle, A. A., Qamar, R., Qamar, R., Jubelirer, S. J., Kurian, S., Salkeni, M. A., Loman, N., Linderholm, B., Silander, G., Hallbeck, A.-L., von Wachenfeldt Väppling, A., Curtit, E., Cardoso, C., Braga, S., Abreu, M., Casa-Nova, M., Nave, M., Ciruelos Gil, E. M., Gelpi, J. B., Ortega, A. F., Padró, J. G., Bermejo de las Heras, B., Cao, M. G., Bañuelos, J. C., Company, J. A., Villaró, G. V., Estevez, L. G., Huober, J., Busch, S., Fehm, T., Hahn, A., Grafe, A., Noesselt, T., Dewitz, T., Wagner, H., Bechtner, C., Weigel, M., Kolberg, H.-C., Decker, T., Thomalla, J., Hesse, T., Harbeck, N., Jens-Uwe Blohmer, J. S., Wolf Sütterlin, M., Altena, R., Chiu, C.-F., Chen, S.-C., Hou, M.-F., Chang, Y.-C., Chen, S.-H., Chen, S.-T., Huang, C.-S., Yeh, D.-C., Yu, J.-C., Tseng, L.-M., Chung, W.-P., Mailliez, A., Petit, T., Delaloge, S., Lévy, C., Dalivoust, P., Extra, J.-M., Mouret-Reynier, M.-A., Hardy-Bessard, A.-C., Simon, H., L'Haridon, T., Mege, A., Giacchetti, S., Chakiba-Brugere, C., Gratet, A., Pottier, V., Ferrero, J.-M., Tennevet, I., Perrin, C., Canon, J.-L., Joris, S., Shao, Z., Xu, B., Jiang, Z., Sun, Q., Shen, K., Pang, D., Zhang, J., Wang, S., Yang, H., Liao, N., Zheng, H., Fu, P., Song, C., Wang, Y., Fan, Z., Geng, C., Tredan, O., Landherr, L., Kaufman, B., Yerushalmi, R., Uziely, B., Conte, P., Zamagni, C., Bianchini, G., De Laurentiis, M., Tondini, C., Gebbia, V., Ciccarese, M., Sarosiek, T., Mackiewicz, J., Słowińska, A., Kalinka, E., Huzarski, T., Im, S.-A., Jung, K. H., Sohn, J. H., Kim, J. H., Lee, K. S., Park, Y. H., Lee, K. E., Chae, Y. S., & Cho, E. K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 33
- Issue
- 12
- Pages
- 1250-1268
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4304084160
- Cited by
- 478
- References
- 25
- FWCI
- 34.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. https://app.cochat.ai/papers/10.1016/j.annonc.2022.09.159
- The paper
- Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmaña, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., . . . Cho, E. K. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.09.159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.